Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
OBJECTIVE
A randomized phase II trial (E1200) was designed to assess toxicities and surgical resection rates in two neoadjuvant gemcitabine-based chemoradiation regimens in patients with borderline resectable pancreatic cancer. The trial was terminated early due to poor accrual.


METHODS
Patients with borderline resectable adenocarcinomas of the pancreas were enrolled. Arm A patients (n = 10) received gemcitabine 500 mg/m(2) IV weekly for 6 weeks, with radiation to 50.4 Gy followed by surgical resection. Arm B patients (n = 11) received preoperative gemcitabine 175 mg/m(2) on days 1, 5, 29, and 33, cisplatin 20 mg/m(2) on days 1-5 and 29-32, 5-FU 600 mg/m(2) on days 1-5 and 29-32, followed by radiation with continuous infusion 5-FU 225 mg/m(2) for 6 weeks. All patients received adjuvant gemcitabine 1,000 mg/m(2) weekly x 3 for five cycles.


RESULTS
Three patients in arm A, and two patients in arm B were resected. Hematologic toxicity was comparable between the two arms except more patients in arm B developed grade 3 or 4 thrombocytopenia than those in arm A. Arm B had fewer grade 1-2 GI toxicities although more patients (45%) experienced grade 3-4 GI toxicity.


CONCLUSIONS
This phase II trial showed that both regimens were tolerable, and resectability and survival were comparable to previous studies.
Landry
Jerome
J
Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA. jerome@radonc.emory.org
Catalano
Paul J
PJ
Staley
Charles
C
Harris
Wayne
W
Hoffman
John
J
Talamonti
Mark
M
Xu
Natalie
N
Cooper
Harry
H
Benson
Al B
AB
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D011878:Radiotherapy / Q000009:adverse effects; D012449:Safety; D016019:Survival Analysis; D000093542:Gemcitabine
D003841:Deoxycytidine; D002945:Cisplatin; D005472:Fluorouracil; D000093542:Gemcitabine
J Clin Oncol. 2003 Sep 15;21(18):3402-8
12885837
Ann Surg. 1987 Sep;206(3):366-73
2820322
Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-24-S7-28
9194476
J Clin Oncol. 2007 May 20;25(15):1960-6
17452677
J Clin Oncol. 1997 Mar;15(3):1087-93
9060549
Surg Oncol Clin N Am. 2004 Oct;13(4):697-709, x
15350943
J Gastrointest Surg. 2003 Sep-Oct;7(6):766-72
13129554
J Surg Oncol. 2002 Nov;81(3):138-43
12407726
J Clin Oncol. 1999 Jul;17(7):2208-12
10561277
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
JAMA. 2008 Mar 5;299(9):1019-26
18319412
Am J Surg. 1996 Jan;171(1):118-24; discussion 124-5
8554125
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):801-8
17379445
Arch Surg. 1985 Aug;120(8):899-903
4015380
Ann Surg Oncol. 2006 Feb;13(2):150-8
16418882
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52
15380578
Ann Oncol. 2002 Oct;13(10):1576-82
12377645
Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4
10615932
Clin Cancer Res. 2001 Aug;7(8):2246-53
11489798
Mayo Clin Proc. 1979 Jul;54(7):468-74
87548